Search results
Results from the WOW.Com Content Network
As an example, the incidence of congestive heart failure is 4.7%, 26% and 48% respectively when patients received doxorubicin at 400 mg/m 2, 550 mg/m 2 and 700 mg/m 2. [4] Therefore, the lifetime cumulative doxorubicin exposure is limited to 400–450 mg/m 2 in order to reduce congestive heart failure incidence to less than 5%, although ...
Other severe side effects include heart disease and tissue death at the site of injection. [2] Use in pregnancy may harm the fetus. [2] Daunorubicin is in the anthracycline family of medication. [3] It works in part by blocking the function of topoisomerase II. [2] Daunorubicin was approved for medical use in the United States in 1979. [2]
The most dangerous side effect of doxorubicin is dilated cardiomyopathy, leading to congestive heart failure. The rate of cardiomyopathy is dependent on its cumulative dose, with an incidence about 4% when the dose of doxorubicin is 500–550 mg/m 2, 18% when the dose is 551–600 mg/m 2 and 36% when the dose exceeds 600 mg/m 2. [19]
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer.Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Infusion of R,C,H and O components of R-CHOP. Red flask contains doxorubicin (H), the most toxic component. Prednisolone (P) is administered on the next four or five days intravenously or in tablets. [1] CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:
Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some chemotherapy regimens as it appears to cause fewer side-effects. Epirubicin has a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar - it has the opposite chirality - which may account for its faster elimination and reduced toxicity.
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
The occurrence of adriamycin-related cardiac toxicity is related to the total lifetime dose of adriamycin, and increases sharply in people who receive a cumulative dose of more than 400 mg/m 2. Almost all patients treated with ABVD receive less than this dose (for 6 cycles of ABVD, the cumulative adriamycin dose is 300 mg/m 2 ); therefore ...